BIO-TECHNE CORP's ticker is TECH and the CUSIP is 09073M104. A total of 431 filers reported holding BIO-TECHNE CORP in Q4 2020. The put-call ratio across all filers is 1.11 and the average weighting 0.2%.
About BIO-TECHNE CORP
Bio-Techne Corp is a leading provider of innovative life science research tools and diagnostic solutions. The company is headquartered in Minneapolis, Minnesota, and has operations in over 50 countries worldwide. Bio-Techne's products and services are used by researchers and clinicians in a wide range of fields, including cancer research, stem cell research, and immunology.
Bio-Techne's success is due in large part to its commitment to innovation and customer service. The company invests heavily in research and development, and has a team of over 1,000 scientists working to develop new products and technologies. Bio-Techne also has a strong focus on customer service, with a dedicated team of technical support specialists available to assist customers with any questions or issues they may have.
In addition to its research tools and diagnostic solutions, Bio-Techne also has a growing portfolio of clinical diagnostic products. The company's Exosome Diagnostics subsidiary is a leader in the development of liquid biopsy tests for cancer diagnosis and monitoring.
Bio-Techne's leadership team is comprised of experienced executives with a track record of success in the life sciences industry. Charles Kummeth, the company's CEO, has been with Bio-Techne since 2013 and has overseen significant growth and expansion during his tenure.
Overall, Bio-Techne is a company with a strong reputation for innovation, customer service, and leadership in the life sciences industry. With a growing portfolio of products and services, the company is well-positioned for continued success in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $37,896,204 | +11.1% | 556,724 | +21.1% | 0.02% | 0.0% |
| Q2 2023 | $34,112,708 | 0.0% | 459,802 | 0.0% | 0.02% | 0.0% |
| Q1 2023 | $34,112,708 | -10.5% | 459,802 | -0.0% | 0.02% | -15.0% |
| Q4 2022 | $38,126,374 | -99.9% | 460,019 | +292.3% | 0.02% | +5.3% |
| Q3 2022 | $33,303,260,000 | -28.6% | 117,265 | -12.9% | 0.02% | -20.8% |
| Q2 2022 | $46,664,329,000 | -25.0% | 134,619 | -6.3% | 0.02% | -11.1% |
| Q1 2022 | $62,184,111,000 | -14.5% | 143,599 | +2.2% | 0.03% | -3.6% |
| Q4 2021 | $72,722,484,000 | +8.9% | 140,570 | +2.0% | 0.03% | 0.0% |
| Q3 2021 | $66,788,284,000 | +15.9% | 137,830 | +7.7% | 0.03% | +12.0% |
| Q2 2021 | $57,603,112,000 | +87.2% | 127,933 | +58.8% | 0.02% | +78.6% |
| Q1 2021 | $30,771,719,000 | +21.2% | 80,569 | +0.7% | 0.01% | +16.7% |
| Q4 2020 | $25,397,015,000 | +49.1% | 79,978 | +16.3% | 0.01% | +33.3% |
| Q3 2020 | $17,037,385,000 | -2.6% | 68,774 | +3.8% | 0.01% | -18.2% |
| Q2 2020 | $17,493,315,000 | +73.1% | 66,245 | +24.3% | 0.01% | +57.1% |
| Q1 2020 | $10,103,333,000 | -3.4% | 53,282 | +11.9% | 0.01% | +16.7% |
| Q4 2019 | $10,456,578,000 | +11.6% | 47,636 | -0.5% | 0.01% | 0.0% |
| Q3 2019 | $9,367,702,000 | +0.4% | 47,875 | +7.0% | 0.01% | -14.3% |
| Q2 2019 | $9,330,344,000 | +10.3% | 44,752 | +5.1% | 0.01% | +16.7% |
| Q1 2019 | $8,455,649,000 | +63.6% | 42,587 | +19.3% | 0.01% | +50.0% |
| Q4 2018 | $5,167,951,000 | -28.7% | 35,710 | +0.6% | 0.00% | -20.0% |
| Q3 2018 | $7,246,312,000 | +49.4% | 35,502 | +8.3% | 0.01% | +25.0% |
| Q2 2018 | $4,851,133,000 | -1.9% | 32,789 | +0.2% | 0.00% | 0.0% |
| Q1 2018 | $4,942,634,000 | +23.8% | 32,724 | +6.2% | 0.00% | +33.3% |
| Q4 2017 | $3,991,046,000 | +1.7% | 30,807 | -5.1% | 0.00% | -25.0% |
| Q3 2017 | $3,924,573,000 | +18.0% | 32,464 | +14.7% | 0.00% | +33.3% |
| Q2 2017 | $3,325,840,000 | +35.1% | 28,305 | +16.8% | 0.00% | 0.0% |
| Q1 2017 | $2,462,371,000 | +109925.5% | 24,224 | +11.3% | 0.00% | 0.0% |
| Q4 2016 | $2,238,000 | -33.8% | 21,771 | -29.5% | 0.00% | -25.0% |
| Q3 2016 | $3,380,000 | -1.3% | 30,869 | +1.6% | 0.00% | 0.0% |
| Q2 2016 | $3,425,000 | +24.4% | 30,369 | +4.2% | 0.00% | +33.3% |
| Q1 2016 | $2,754,000 | -7.1% | 29,134 | -11.5% | 0.00% | 0.0% |
| Q4 2015 | $2,963,000 | -0.4% | 32,923 | +2.3% | 0.00% | 0.0% |
| Q3 2015 | $2,976,000 | +26.3% | 32,183 | +34.4% | 0.00% | +50.0% |
| Q2 2015 | $2,357,000 | +6.6% | 23,937 | +8.6% | 0.00% | 0.0% |
| Q1 2015 | $2,211,000 | +12.1% | 22,050 | +3.3% | 0.00% | 0.0% |
| Q4 2014 | $1,973,000 | – | 21,350 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Broadcrest Asset Management, LLC | 300,000 | $24,489,000 | 21.05% |
| Montanaro Asset Management Ltd | 388,800 | $31,737,744 | 5.02% |
| Sandhill Capital Partners LLC | 502,447 | $41,014,775 | 3.74% |
| Brown Capital Management | 3,160,892 | $258,023,614 | 3.66% |
| DF DENT & CO INC | 3,275,617 | $267,388,640 | 3.62% |
| Ownership Capital B.V. | 2,282,104 | $186,288,150 | 3.26% |
| Jackson Square Partners, LLC | 1,361,789 | $111,162,836 | 3.24% |
| STONE RUN CAPITAL, LLC | 88,135 | $7,194,460 | 3.20% |
| Pembroke Management, LTD | 339,591 | $27,720,813 | 2.99% |
| Summit Creek Advisors LLC | 283,693 | $23,157,860 | 2.90% |